Watchdog says, Remdesivir could cost up to USD$4,490 per dose - GazeFeed

Watchdog says, Remdesivir could cost up to USD$4,490 per dose - GazeFeed

The Institute for Clinical and Economic Review (ICER) says that Gilead Sciences, makers of the now-authorized COVID-19 therapy Remdesivir can charge up to USD$4,460.00 per patient.


Remdesivir - is the first coronavirus treatment to show clinical benefits, is found to be cost-effective at that price point. That could mean big money for Gilead Sciences, which could theoretically make as much as (1)USD$ billion this year. Gilead Sciences is ramping up its supply of Remdesivir, aiming to treat 1 million patients by the end of 2020. 

Currently, Gilead Sciences is giving Remdesivir to the US Government for free, and will continue to do so until its current supply of 1.5 million doses is exhausted.

The company is looking to treat 140,000 patients, each with a ten day regimen of the drug. Patients suffering from less severe cases of COVID-19 will be treated to a five day regimen.


The company has not released public information about future pricing of the drug. However, the US Government’s Biomedical Advanced Research and Development Authority (BARDA) is now providing USD$483 million to develop and manufacture vaccine candidates.

Gilead Sciences is promising to ensure affordability and access to the said drug of the deadly virus.

According to the NIH’s National Institute of Allergy and Infectious Diseases, taking the drug cut recovery time by 4 days.

Engage with us via comment or if you have some business proposals or collaborations you can send it here in our official email:

via | GazeFeed

Post a Comment